Zongertinib

Last updated

Zongertinib
Zongertinib.svg
Clinical data
Trade names Hernexeos
Other namesBI-1810631, BI1810631
License data
Routes of
administration 		By mouth
Drug class Antineoplastic, epidermal growth factor receptor 2 (HER2) inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
  • N-(1-{4-[3-methyl-4-(1-methylbenzimidazol-5-yl)oxyanilino]pyrimido[5,4-d]pyrimidin-6-yl}piperidin-4-yl)prop-2-enamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C29H29N9O2
Molar mass 535.612 g·mol−1
3D model (JSmol)
  • C=CC(=O)NC1CCN(c2ncc3ncnc(Nc4ccc(Oc5ccc6c(c5)ncn6C)c(C)c4)c3n2)CC1
  • InChI=1S/C29H29N9O2/c1-4-26(39)34-19-9-11-38(12-10-19)29-30-15-23-27(36-29)28(32-16-31-23)35-20-5-8-25(18(2)13-20)40-21-6-7-24-22(14-21)33-17-37(24)3/h4-8,13-17,19H,1,9-12H2,2-3H3,(H,34,39)(H,31,32,35)
  • Key:YSGNGFPNTLERCR-UHFFFAOYSA-N

Zongertinib, sold under the brand name Hernexeos, is an anti-cancer medication used for the treatment of non-small cell lung cancer. [1] [2] Zongertinib is a kinase inhibitor of human epidermal growth factor receptor 2 (HER2). [1] [3] [4] It is taken by mouth. [1]

Contents

Zongertinib was approved for medical use in the United States in August 2025. [5]

Medical uses

Zongertinib is indicated for the treatment of adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. [1] [5]

Adverse effects

The US Food and Drug Administration prescribing information includes warnings and precautions for hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryo-fetal toxicity. [1] [5]

History

Efficacy was evaluated in participants with unresectable or metastatic, non-squamous non-small cell lung cancer with HER2 (ERBB2) TKD mutations who had received prior systemic therapy and received zongertinib in Beamion LUNG-1 (NCT04886804), an open-label, multi-center, multi-cohort trial. [5] The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) determined by blinded independent central review per RECIST v1.1. [5]

The US Food and Drug Administration granted the application for zongertinib priority review, breakthrough therapy, and fast track designations. [5]

Society and culture

Zongertinib was approved for medical use in the United States in August 2025. [2] [6]

Names

Zongertinib is the international nonproprietary name [7] and the United States Adopted Name. [8]

Zongertinib is sold under the brand name Hernexeos. [2] [6]

References

  1. 1 2 3 4 5 6 "Hernexeos (zongertinib tablets), for oral use" (PDF). Product Insert. Boehringer Ingelheim Pharmaceuticals, Inc.
  2. 1 2 3 "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 8 August 2025. Retrieved 10 August 2025.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  3. ↑ Trillo Aliaga P, Spitaleri G, Attili I, Corvaja C, Battaiotto E, Angelopoulos PA, et al. (June 2025). "HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top". Molecules. 30 (12). Basel, Switzerland: 2645. doi: 10.3390/molecules30122645 . PMC   12195848 . PMID   40572608.
  4. ↑ Ismail A, Desai A, Boumber Y (2025). "HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities". Frontiers in Oncology. 15 1624124. doi: 10.3389/fonc.2025.1624124 . PMC   12226463 . PMID   40620714.
  5. 1 2 3 4 5 6 "FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations". U.S. Food and Drug Administration (FDA). 8 August 2025. Retrieved 10 August 2025.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  6. 1 2 "U.S. FDA grants accelerated approval to Boehringer's Hernexeos as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC" (Press release). Boehringer Ingelheim. 8 August 2025. Retrieved 10 August 2025– via GlobeNewswire.
  7. ↑ World Health Organization (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". WHO Drug Information. 37 (3). hdl: 10665/373341 .
  8. ↑ "Zongertinib". American Medical Association. Retrieved 10 August 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.